The GLP-1 Economy

TL;DR

The GLP-1 economy is moving past pure retail competition as major pharmacy benefit managers and federal policy interventions rapidly expand patient access, while downstream medical sectors face severe disruption. Eli Lilly has leveled the playing field against Novo Nordisk through key commercial formulary wins for Zepbound and Foundayo, even as a historic Medicare pilot program prepares to subsidize these therapies for seniors. Meanwhile, the surgical medtech sector is feeling the direct sting of this pharmacological shift, with bariatric surgery rates plunging by over a quarter.

PBM and Formulary Realignments in the Oral and Injectable Battles

Pharmacy benefit managers are aggressively redrawing their coverage maps, turning formulary inclusion into the ultimate weapon in the commercial war between Eli Lilly and Novo Nordisk.

"CVS Caremark has announced that it will add Zepbound (tirzepatide) back to its most common commercial formularies as an additional preferred option, effective Oct. 1, 2026, and will remove the new-to-market block on Foundayo (orforglipron), effective June 1, 2026, for plans that have approved coverage of the drug." — eli-lilly-foundayo-orforglipron-fda-approval (Source: CVS Caremark Expands GLP-1 Formulary Coverage)

This decision by CVS Caremark, the largest U.S. pharmacy benefit manager, strips Novo Nordisk's Wegovy of its exclusive commercial advantage and injects immediate momentum into Lilly's newly approved oral agonist, Foundayo. Although Foundayo’s initial launch generated only about 16,000 weekly prescriptions compared to Wegovy’s much larger volume, eliminating the PBM block is the exact catalyst needed to unlock broad commercial adoption.

What to watch: Watch whether Foundayo's script volume accelerates toward Jefferies' full-year forecast of $1.6 billion once CVS Caremark's block removal takes full effect eli-lilly-foundayo-orforglipron-fda-approval.

Federal Policy Interventions and the Access Breakthrough

The federal government is actively bypassing statutory bans to subsidize weight-loss therapies, setting up a massive, taxpayer-funded expansion of the GLP-1 patient base.

"The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027. The Medicare GLP-1 Bridge will operate outside of the Medicare Part D benefit’s coverage and payment flow." — medicare-glp-1-bridge-program-50-copay (Source: Medicare GLP-1 Bridge | CMS)

By leveraging Section 402 of the Social Security Amendments, the Centers for Medicare & Medicaid Services has engineered a legal workaround to the statutory ban on weight-loss coverage. This pilot removes standard insurance risk and caps beneficiary copays at a flat $50, which will inevitably funnel billions in taxpayer dollars directly to Eli Lilly and Novo Nordisk.

What to watch: Watch how much federal spending escalates once the program launches, and whether Part D sponsors push for permanent legislative coverage changes during this eighteen-month trial medicare-glp-1-bridge-program-50-copay.

The Downstream Cannibalization of Medtech and Invasive Surgery

The rapid adoption of pharmacological weight-loss therapies is directly eroding the volume of invasive metabolic surgeries, presenting a major structural threat to established medical technology giants.

"In the study, researchers analyzed health insurance data from over 17 million people in the U.S. They found that between 2022 and 2023, prescriptions of GLP-1 medications for obesity patients more than doubled, while the rate of bariatric surgery decreased by 25.6%." — glp1-impact-medtech-bariatric-surgery-decline (Source: Rise in obesity drug use linked with decrease in weight-loss surgery)

This dramatic 25.6% drop in bariatric procedures signals that patients are aggressively opting for non-invasive medical management over traditional anatomical modifications like gastric bypass. For medtech manufacturers like Intuitive Surgical, whose robotic systems are heavily utilized in these operations, this represents a significant headwind that could permanently cap procedure growth in the metabolic space.

What to watch: Watch whether the decline in bariatric surgeries stabilizes as clinicians attempt to position GLP-1 therapies and surgery as complementary tools rather than mutually exclusive choices glp1-impact-medtech-bariatric-surgery-decline.

What surprised us

• The CMS Legal End-Run: The legal gymnastics deployed by the Centers for Medicare & Medicaid Services to bypass a statutory ban is stunning medicare-glp-1-bridge-program-50-copay. By invoking an obscure mid-century amendment to launch the Bridge program, the agency has effectively shifted billions of dollars of weight-loss drug costs directly onto taxpayers, completely sidestepping private insurer risk medicare-glp-1-bridge-program-50-copay.
• The Direct-to-Patient Telehealth Heavyweight: Eli Lilly's early launch dynamics for Foundayo demonstrate that traditional retail pharmacies are being left in the dust eli-lilly-foundayo-orforglipron-fda-approval. With nearly half of early prescriptions coming through LillyDirect and over a third from telehealth, the classic doctor-to-retail pipeline has been completely upended by digital-first distribution eli-lilly-foundayo-orforglipron-fda-approval.
• The Absolute Cliff-Face in Medtech: We expected GLP-1s to slow down bariatric surgery, but a 25.6% drop in a single year is a structural shockwave glp1-impact-medtech-bariatric-surgery-decline. This swift behavioral shift poses an immediate existential threat to robotic and laparoscopic surgery volumes, proving that pharmacological convenience beats the surgical suite faster than anyone predicted glp1-impact-medtech-bariatric-surgery-decline.

Open threads worth a vote

• [GLP-1 Ripple Effects: Food & Beverage, Medtech, and Insurance Dynamics](/topics/019e84f3-e46c-7c64-bcce-6d0ef82f7c3f#threads)

Since last time

• Promoted
  • Federal Policy Interventions: The Medicare GLP-1 Bridge program is now a core focus, shifting from a hypothetical to a concrete, taxpayer-funded reality.
  • Medtech Disruption: The impact on bariatric surgery, previously an open thread, is now a primary section detailing a 25.6% decline in procedure volume.
• Escalated
  • Lilly vs. Novo Nordisk: The competition has moved from "format wars" (oral vs. injectable) to "formulary wars." The focus is now on PBM coverage and formulary access rather than drug delivery mechanisms.
• Demoted
  • Lilly’s Pricing Model: The specific analysis of the $149 price point has been reduced to a passing mention within the "What surprised us" section regarding distribution channels.
• Disappeared
  • Biotech Challengers: Structure Therapeutics and Viking Therapeutics are no longer mentioned.
  • Next-Gen Dosing: Amgen’s MariTide and the broader discussion of monthly dosing/tolerability optimization are entirely absent.
• Unchanged
  • None. The briefing has shifted entirely from clinical/format innovation to commercial/policy/market impact.

PBM and Formulary Realignments (Escalated)

The battle between Eli Lilly and Novo Nordisk has shifted from clinical "format wars" to commercial "formulary wars." Pharmacy benefit managers (PBMs) are now the primary arbiters of market share, with CVS Caremark’s latest move fundamentally altering the landscape for both Zepbound and Foundayo.

"CVS Caremark has announced that it will add Zepbound (tirzepatide) back to its most common commercial formularies as an additional preferred option, effective Oct. 1, 2026, and will remove the new-to-market block on Foundayo (orforglipron), effective June 1, 2026, for plans that have approved coverage of the drug." — eli-lilly-foundayo-orforglipron-fda-approval (Source: CVS Caremark Expands GLP-1 Formulary Coverage)

This decision strips Novo Nordisk's Wegovy of its exclusive commercial advantage. While Foundayo’s initial launch was modest (16,000 weekly prescriptions), the removal of the PBM block is the critical catalyst for broad commercial adoption.

What to watch: Watch whether Foundayo's script volume accelerates toward Jefferies' full-year forecast of $1.6 billion now that the CVS Caremark block is removed eli-lilly-foundayo-orforglipron-fda-approval.

Federal Policy Interventions and the Access Breakthrough (Promoted)

The federal government is bypassing statutory bans to subsidize weight-loss therapies, creating a massive, taxpayer-funded expansion of the patient base.

"The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027. The Medicare GLP-1 Bridge will operate outside of the Medicare Part D benefit’s coverage and payment flow." — medicare-glp-1-bridge-program-50-copay (Source: Medicare GLP-1 Bridge | CMS)

By leveraging Section 402 of the Social Security Amendments, CMS has engineered a legal workaround to the statutory ban on weight-loss coverage, capping beneficiary copays at $50.

What to watch: Watch how federal spending escalates during this eighteen-month trial and whether Part D sponsors push for permanent legislative coverage changes medicare-glp-1-bridge-program-50-copay.

The Downstream Cannibalization of Medtech (Promoted)

The rapid adoption of pharmacological weight-loss therapies is directly eroding the volume of invasive metabolic surgeries, presenting a structural threat to established medical technology giants.

"In the study, researchers analyzed health insurance data from over 17 million people in the U.S. They found that between 2022 and 2023, prescriptions of GLP-1 medications for obesity patients more than doubled, while the rate of bariatric surgery decreased by 25.6%." — glp1-impact-medtech-bariatric-surgery-decline (Source: Rise in obesity drug use linked with decrease in weight-loss surgery)

This 25.6% drop signals that patients are opting for non-invasive medical management over traditional anatomical modifications, creating a significant headwind for companies like Intuitive Surgical.

What to watch: Watch whether the decline in bariatric surgeries stabilizes as clinicians attempt to position GLP-1 therapies and surgery as complementary tools rather than mutually exclusive choices glp1-impact-medtech-bariatric-surgery-decline.

What surprised us

• The CMS Legal End-Run: [NEW] The legal gymnastics deployed by CMS to bypass a statutory ban is stunning. By invoking an obscure mid-century amendment to launch the Bridge program, the agency has effectively shifted billions of dollars of weight-loss drug costs directly onto taxpayers medicare-glp-1-bridge-program-50-copay.
• The Direct-to-Patient Telehealth Heavyweight: [NEW] Eli Lilly's early launch dynamics for Foundayo demonstrate that traditional retail pharmacies are being left in the dust. With nearly half of early prescriptions coming through LillyDirect and over a third from telehealth, the classic doctor-to-retail pipeline has been completely upended eli-lilly-foundayo-orforglipron-fda-approval.
• The Absolute Cliff-Face in Medtech: [NEW] We expected GLP-1s to slow down bariatric surgery, but a 25.6% drop in a single year is a structural shockwave. This swift behavioral shift poses an immediate existential threat to robotic and laparoscopic surgery volumes glp1-impact-medtech-bariatric-surgery-decline.

Open threads

• GLP-1 Ripple Effects: This thread is now closed; the impact on medtech and insurance dynamics has been absorbed into the body of this briefing.